Autoimmune therapy - Remedy Plan Therapeutics
Latest Information Update: 03 Jan 2024
At a glance
- Originator Remedy Plan Therapeutics
- Class
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 27 Nov 2023 Early research in Autoimmune disorders in USA (unspecified route) prior to November 2023 (Remedy Plan Therapeutics pipeline, November 2023)